Erenumab-Aooe

Introduction Overview

Generic Name

erenumab-aooe

Brand Name

Aimovig

Dosage Form

subcutaneous injection via autoinjector or prefilled syringe (70 mg/mL, 140 mg/mL)

Drug Class

Calcitonin Gene-Related Peptide (CGRP) inhibitors

Pharmacokinetics

Absorption

Aimovig is administered as a subcutaneous injection and is slowly absorbed into systemic circulation. Peak serum concentrations are typically reached within 4 to 6 days post-injection. The subcutaneous route allows for gradual uptake into the bloodstream, supporting once-monthly dosing. Absorption can be influenced by the injection site, with abdomen, thigh, or upper arm commonly used to optimize bioavailability. Clinical data indicate consistent absorption profiles in adult patients, and steady-state plasma concentrations are generally achieved within three months of monthly dosing.

Distribution

Erenumab circulates predominantly as an intact monoclonal antibody, with a volume of distribution approximately equivalent to plasma volume, suggestive of limited extravascular distribution. Due to its large molecular size and monoclonal antibody properties, it does not readily cross the blood-brain barrier, acting primarily at peripheral sites. Binding to CGRP receptors occurs principally in vascular and neuronal tissues implicated in migraine pathophysiology. The drug exhibits limited tissue penetration beyond the plasma and extracellular fluids.

Metabolism

Metabolism of erenumab occurs via proteolytic degradation pathways typical of immunoglobulin G (IgG) monoclonal antibodies. These enzymatic processes break down the molecule into small peptides and amino acids which are then recycled or eliminated. There is no involvement of hepatic cytochrome P450 enzymes; thus, erenumab metabolism avoids typical hepatic metabolic pathways and associated drug-drug interactions. Its catabolism follows the general antibody turnover mechanisms seen for biological therapeutics.

Elimination

Erenumab is eliminated primarily by proteolytic catabolism throughout the body rather than renal or hepatic elimination routes. The terminal half-life is approximately 28 days, supporting its once-monthly dosing schedule. Clearance can vary slightly depending on patient factors, but generally remains consistent without accumulation over months of treatment. This elimination profile reduces the likelihood of renal or hepatic impairment affecting drug levels significantly.

Dosage Forms

Adults

Aimovig is prescribed as a 70 mg subcutaneous injection once monthly. For certain patients, particularly those with suboptimal response, the dosage may be increased to 140 mg once monthly. Dose adjustments are not generally required for renal or hepatic impairment due to its metabolism and elimination pathways.

Adolescents

Currently, Aimovig use in adolescents under 18 years of age has not been established or approved; clinical safety and efficacy data are insufficient in this population, thus use is not recommended unless advised by a specialist.

Special Populations

Aimovig does not require dose adjustments in elderly patients or those with mild to moderate renal or hepatic impairment, given its catabolic clearance mechanisms. There is insufficient data in severe hepatic or renal impairment, so caution is advised. Aimovig’s safety in pregnant or breastfeeding women has not been firmly established, and it should be used only if the benefits outweigh potential risks. No formal pediatric dosing guidelines exist due to lack of data in this group. No dose modification is required based on sex or ethnicity as pharmacokinetic studies show no clinically relevant differences.

Mechanism Of Action

Aimovig (erenumab-aooe) functions as a fully human monoclonal antibody that selectively binds to the calcitonin gene-related peptide (CGRP) receptor, blocking CGRP from activating this receptor. CGRP is a neuropeptide extensively involved in vasodilation of cerebral and dural blood vessels, neurogenic inflammation, and pain transmission that are central to migraine pathogenesis. By inhibiting the CGRP receptor, Aimovig prevents the downstream signaling pathways responsible for vasodilation and inflammation during migraine attacks.

The drug binds with high affinity and specificity to the canonical CGRP receptor complex, a heterodimeric G protein-coupled receptor composed of the calcitonin receptor-like receptor and receptor activity-modifying protein 1 (RAMP1). This blockade prevents CGRP from binding and activating adenylate cyclase-mediated cyclic AMP pathways, thus inhibiting the vasodilatory and proinflammatory effects elicited by CGRP.

Unlike small molecule CGRP antagonists, Aimovig acts extracellularly by preventing receptor activation without penetrating cells, providing targeted modulation with potentially fewer off-target effects. The long half-life supports sustained receptor blockade, making it an effective prophylactic agent reducing the frequency of migraine attacks rather than treating acute episodes.

Clinical studies have demonstrated that by interrupting CGRP signaling, Aimovig effectively decreases the number of migraine days per month, improves quality of life, and is well tolerated in adult patients. Its mechanism is distinct from traditional migraine medications such as beta-blockers, antiepileptics, or NSAIDs, making it a novel targeted therapy in migraine prophylaxis.

Pharmacological Actions

Selective antagonism of CGRP receptor, inhibiting CGRP-mediated vasodilation and neurogenic inflammation
Reduction in frequency and severity of migraine attacks through prevention of migraine pathophysiology
Long-acting receptor blockade supporting once-monthly prophylactic dosing
Subcutaneous administration leading to systemic CGRP receptor inhibition
Minimal off-target interactions due to high specificity for CGRP receptor
Modulation of trigeminovascular pathway implicated in migraine pain signaling
Non-acute action; effective as preventive therapy rather than abortive treatment
Decreased release of proinflammatory neuropeptides associated with migraine
Potential reduction in central sensitization related to migraine progression
Favorable safety profile with low immunogenicity as a human monoclonal antibody
No significant alteration of hepatic enzymes or cytochrome P450 metabolism
Limited CNS penetration, reducing central nervous system adverse effects
Decreased vascular permeability and edema in migraine-related tissues
Improvement in patient quality of life by decreasing migraine burden
Demonstrated efficacy in both episodic and chronic migraine prevention

Therapeutic Clinical Uses

Prevention of episodic migraine in adult patients
Prevention of chronic migraine in adults
Reduction of monthly migraine days in patients with established migraine diagnosis
Use as a prophylactic agent in patients intolerant or nonresponsive to traditional migraine preventives
Treatment option for patients seeking once-monthly injectable migraine prevention
Reduction in migraine-associated disability and improvement in functional capacity
Adjunct therapy in migraine management protocols
Use in patients with frequent migraine attacks to decrease attack frequency
Employed in patients with contraindications to oral migraine preventive medications
Alternative to beta-blockers, antiepileptics, or antidepressants for migraine prophylaxis
Potential use in patients with comorbidities limiting other migraine preventives
Improving adherence due to monthly dosing regimen
Use in patients who prefer injectable over oral preventive medications
Prophylaxis in patients with moderate to severe migraine burden
Reducing reliance on acute migraine treatments through preventive effect

Side Or Adverse Effects

Injection site reactions including pain, redness, swelling (5-6%)
Constipation occurring in 1-3% of patients, occasionally severe
Muscle cramps and spasms in a small percentage (<2%)
Potential for serious allergic reactions such as rash, swelling, or hives
Rare but severe constipation potentially requiring hospitalization or surgery
Possible new onset or worsening of hypertension reported
Headache, fatigue, or dizziness as uncommon adverse events
No significant liver enzyme elevations reported
Low incidence of immunogenicity or anti-drug antibody formation
Absence of systemic allergic reactions in the majority of patients
No reported alopecia from clinical trials, with rare postmarketing reports
Possible injection site discomfort or bruising
Uncommon nausea or gastrointestinal discomfort
Rare hypersensitivity phenomena including facial or throat swelling
Minimal systemic adverse events typical of monoclonal antibody therapies

Precautions

Monitor patients for signs of constipation, especially severe or persistent
Assess blood pressure before and during treatment due to risk of hypertension
Avoid injection in areas of skin that are red, tender, bruised or hard
Evaluate history of hypersensitivity or allergic reactions to monoclonal antibodies before initiation
Exercise caution in pregnant women; use only if benefits outweigh risks
Consider the absence of data in pediatric patients; not recommended under 18 years
Monitor for any new or worsening cardiovascular symptoms
Inform patients about potential injection site reactions
Avoid abrupt discontinuation to maintain migraine control
Use cautiously in patients with gastrointestinal disorders due to constipation risk
Educate patients on proper injection technique to reduce local adverse effects
Advise patients to report any signs of allergic reaction immediately
Consider comorbid conditions that may be exacerbated by changes in vascular tone
Assess for concomitant medication use that might influence gastrointestinal motility
Ensure safe disposal of autoinjectors and syringes to prevent needlestick injuries

Warnings

Serious hypersensitivity reactions can occur hours to days after administration including anaphylaxis
Severe constipation with complications like bowel obstruction requiring hospitalization has been reported
May cause new onset or worsening hypertension; blood pressure monitoring recommended
Not indicated for treatment of acute migraine attacks
Do not use if allergic to erenumab or any components of the formulation
Careful screening for potential risk factors for gastrointestinal complications advised
Injection site reactions are common but usually mild and self-limited
Use with caution in pregnant or breastfeeding women due to lack of safety data
Avoid use in patients with known hypersensitivity to monoclonal antibodies
Patients should be informed that the drug is a preventive, not abortive, treatment
Monitor patients for any signs of hypersensitivity post-injection
Potential impact on vascular homeostasis necessitates vigilance in cardiovascular patients
Ensure appropriate storage conditions to maintain drug efficacy and safety
Avoid shaking or freezing the product to prevent degradation
Promptly seek emergency care if signs of severe allergic reaction occur

Contraindications

Known hypersensitivity to erenumab-aooe or any component of the formulation
History of severe allergic reaction to monoclonal antibodies targeting CGRP receptor
Use in pediatric patients under 18 years due to lack of safety and efficacy data
Patients with active gastrointestinal obstruction or severe bowel disease at risk from constipation
Not suitable for treatment of acute migraine attacks
Contraindicated if injection site skin is infected, inflamed, or damaged
Use cautiously in patients with uncontrolled hypertension
Avoid use in patients with hypersensitivity to any inactive ingredients such as polysorbate 80
Contraindicated if patient has experienced anaphylaxis with prior doses
Avoid concurrent use with other CGRP pathway antagonists due to unknown additive effects

Drug Interactions

No significant drug-drug interactions have been identified due to non-reliance on cytochrome P450 metabolism
Low potential for interaction with common medications including antihypertensives, analgesics, or anticonvulsants
No known interactions with acute migraine therapies such as triptans or NSAIDs
No evidence of interaction with herbal supplements or vitamins
Concomitant use with other CGRP receptor antagonists or monoclonal antibodies is not recommended
No adjustment needed when co-administered with drugs metabolized by CYP enzymes
No reported effects on coagulation or antiplatelet agents
No documented interaction with oral contraceptives or hormone replacement therapy
Caution if used alongside medications affecting gastrointestinal motility due to additive constipation risk
Limited data on interaction with immunosuppressive agents, recommend monitoring
No interaction with alcohol documented but alcohol may trigger migraines independently
No interaction with beta-blockers or antiepileptics used concomitantly for migraine prevention
No effect on the pharmacokinetics of common cardiovascular drugs
No need to alter dosing of Aimovig or other drugs during co-administration identified
Monitor patient response when starting or stopping medications with blood pressure effects

Preparations Of The Drug

Aimovig 70 mg/mL prefilled SureClick autoinjector, single-dose syringe
Aimovig 140 mg/mL prefilled SureClick autoinjector, single-dose syringe
Aimovig 70 mg/mL solution in single-dose prefilled syringe (discontinued in some markets)
Aimovig 140 mg/mL solution in single-dose prefilled syringe (discontinued in some markets)
Packaged in cartons containing one autoinjector or syringe
Stored refrigerated between 2°C and 8°C (36°F to 46°F)
Room temperature stability for up to 7 days after removal from refrigerator
Contains inactive ingredients including acetate, polysorbate 80, and sucrose
Supplied with sharps disposal container recommendations for single-use administration
Available only by prescription
No generic formulations currently available
Commercially distributed by Amgen Inc.